- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02298842
In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Platelets suspended in platelet additive solutions (PAS) have been collected and transfused in Europe for over 20 years. These PAS solutions outside of the United States (US) are not tied to an apheresis device; however in the US, PAS solutions have traditionally been linked to a corresponding apheresis device.
Currently in the US, there are two solutions approved by the Food and Drug Administration (FDA) as a PAS for the replacement of 65% plasma in platelet components. Isoplate Solution is approved for use with the Trima Accel® Automated Blood Collection System (Trima Accel System) and InterSol Solution is approved for use with the Amicus Separator System.
This study is designed to provide blood centers with the option to use either Isoplate or InterSol when collecting platelets for use with PAS. Terumo BCT is pursuing approval for InterSol Solution in combination with the Trima Accel System.
This is a randomized, paired, prospective, open-label, multi-center study. Up to 120 healthy adult subjects will be enrolled in this study to ensure 60 paired evaluable data points across two Investigational Sites. Evaluable is defined as two completed platelet products with 100mL plasma that do not meet any of the protocol analysis exclusion criteria.
The additional platelet donors account for screen failures, incomplete procedures, and protocol exclusions.
Two units of platelets will be collected from each subject: one Test unit collected as a hyperconcentrated platelet product with 100 mL of concurrent plasma and one Control unit of platelets in plasma collected according to standard procedure. The Test unit will be suspended in 65% Intersol/35% plasma immediately after collection; the Control unit will be maintained in 100% plasma.
Eligible donors who have signed an informed consent will be enrolled. Randomization will occur in a ratio of 1:1 to one of the following Treatment Arms:
Arm A: Collection of one Test unit followed by collection of one Control unit Arm B: Collection of one Control unit followed by collection of one Test unit
The standard apheresis platelet units collected in the Control arm will mirror the hyperconcentrated platelet units in the Test arm in terms of yield and final concentration.
SUBJECT PROCEDURES
Screening can be performed within 30 days of the apheresis procedure or combined with the first Apheresis Visit.
The following evaluations will be performed:
- Informed consent will be obtained prior to initiating any study specific procedures
- Eligibility will be confirmed
- Demographics (age, gender, ethnic origin), height, and weight
- Complete blood count (CBC) for hemoglobin and platelet count on subjects new to the Investigative Site that do not have historical hemoglobin and/or platelet count measurements
Apheresis Visit
The following procedures will be performed at both the first and second Apheresis Visits:
- Eligibility will be confirmed
- Finger stick hemoglobin
- First apheresis procedure will be performed
Subject will return to the Site in 6 to 8 days following the first apheresis collection for the second apheresis collection. This will conclude the subject's participation.
Apheresis procedures will be run according to the instructions and precautions described in the commercially available Trima Accel Operator's Manual for use with Version 6.4.
The Investigator or designee will perform the venipuncture, monitor the subject during the collection, assess and provide any interventions for adverse effects, remove the needle, dress the puncture site and monitor subject through recovery.
The following will be documented:
- Trima Procedure details
- Adverse events
- Medications to treat AEs
- Device deficiencies
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Hoxworth Blood Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53233
- Blood Center of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years of age or older
- Meet the inclusion criteria defined by the Investigational Site for an apheresis double platelet with plasma collection on the Trima Accel System. These criteria are based on American Association of Blood Banks (AABB) standards. Note: Subjects who are deferred from volunteer community donations because of travel restrictions, piercings or tattoos may participate in the study.
Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Platelets Stored in Plasma
Platelets stored in Plasma
|
A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components.
After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient.
To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure.
During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage.
The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
|
Experimental: Test Platelets Stored in InterSol
Platelets stored in InterSol
|
A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components.
After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient.
To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure.
Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage.
The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pH of Platelets at Day 5
Time Frame: Day 5
|
The primary endpoint for this study is pH of platelets stored in InterSol at Day 5.
The FDA acceptance criteria for pH is 95% of products have pH >6.2 at 22 degrees C with 95% confidence interval.
A sample size of 60 subjects was chosen for the study to meet the acceptance criteria with 0 failures out of 60 Test products.
|
Day 5
|
pH of Platelets at Day 7
Time Frame: Day 7
|
The primary endpoint for this study is pH of platelets stored in InterSol at Day 7. The FDA acceptance criteria for pH is 95% of products have pH >6.2 at 22 degrees C with 95% confidence interval.
A sample size of 60 subjects was chosen for the study to meet the acceptance criteria with 0 failures out of 60 Test products.
|
Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Platelets Activated as Measured by P-selectin
Time Frame: Day 5
|
Flow cytometric detection of platelet P-selectin expression (Units: %).
Lower value is considered to indicate better platelet quality.
|
Day 5
|
Percent of Extent of Shape Change
Time Frame: Day 5
|
Measures the proportion of platelets that have a discoid morphology (Units: %).
Higher value is considered to indicate better platelet quality.
|
Day 5
|
Percent of Platelets Exhibiting Hypotonic Shock Response
Time Frame: Day 5
|
Measures the ability of platelets to recover their volume after being exposed to a hypotonic environment (Units: % Recovery).
Higher value is considered to indicate better platelet quality.
|
Day 5
|
Platelet Morphology
Time Frame: Day 5
|
Quantifies (via phase-contrast light microscopy) the morphological changes of platelets coincident with the full range of platelet activation profile (Units: Kunicki score; Range is 0 to 400).
Higher values represent healthier platelets.
|
Day 5
|
Percent of Platelets Activated as Measured by P-selectin
Time Frame: Day 7
|
Flow cytometric detection of platelet P-selectin expression (Units: %).
Lower value is considered to indicate better platelet quality.
|
Day 7
|
Percent of Extent of Shape Change
Time Frame: Day 7
|
Measures the proportion of platelets that have a discoid morphology (Units: %).
Higher value is considered to indicate better platelet quality.
Higher value is considered to indicate better platelet quality.
|
Day 7
|
Percent of Platelets Exhibiting Hypotonic Shock Response
Time Frame: Day 7
|
Measures the ability of platelets to recover their volume after being exposed to a hypotonic environment (Units: % Recovery).
Higher value is considered to indicate better platelet quality.
|
Day 7
|
Platelet Morphology
Time Frame: Day 7
|
Quantifies (via phase-contrast light microscopy) the morphological changes of platelets coincident with the full range of platelet activation profile (Units: Kunicki score; Range is 0 to 400).
Higher values represent healthier platelets.
|
Day 7
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jose Cancelas-Perez, MD, PhD, Hoxworth Blood Center
- Principal Investigator: Mehraboon S Irani, MD, Clood Center of Wisconsin
Publications and helpful links
General Publications
- Dumont LJ, Cancelas JA, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion. 2013 May;53(5):972-80. doi: 10.1111/j.1537-2995.2012.03841.x. Epub 2012 Aug 6.
- Ringwald J, Walz S, Zimmermann R, Zingsem J, Strasser E, Weisbach V, Eckstein R. Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality. Vox Sang. 2005 Jul;89(1):11-8. doi: 10.1111/j.1423-0410.2005.00645.x.
- Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, Cushing M, Shaz B, Mair D, Brantigan B, Heaton WA. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion. 2014 Aug;54(8):1927-34. doi: 10.1111/trf.12597. Epub 2014 Apr 16.
- Diedrich B, Sandgren P, Jansson B, Gulliksson H, Svensson L, Shanwell A. In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution. Vox Sang. 2008 Feb;94(2):96-102. doi: 10.1111/j.1423-0410.2007.01002.x. Epub 2007 Nov 22.
- Gulliksson H, AuBuchon JP, Vesterinen M, Sandgren P, Larsson S, Pickard CA, Herschel I, Roger J, Tracy JE, Langweiler M; Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium. Vox Sang. 2002 Apr;82(3):131-6. doi: 10.1046/j.1423-0410.2002.drfgv158.x.
- Dumont LJ, VandenBroeke T, Ault KA. Platelet surface P-selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfus Med Rev. 1999 Jan;13(1):31-42. doi: 10.1016/s0887-7963(99)80086-8. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CTS-5051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Platelets stored in Plasma
-
Moritz Stolla, MDUnited States Department of DefenseRecruitingHemorrhage | Bleeding | Surgical Blood Loss | Platelets; DefectUnited States
-
Australian and New Zealand Intensive Care Research...Australian Red CrossActive, not recruiting
-
Haukeland University HospitalCompletedBleeding | Surgery | Cardiovascular Disease OtherNorway
-
Jason SperryUnited States Department of DefenseActive, not recruiting
-
Jason SperryUnited States Department of DefenseCompleted
-
Philip SpinellaWashington University School of Medicine; United States Department of Defense; University of Pittsburgh and other collaboratorsRecruiting
-
University of Campinas, BrazilUnknown
-
Medical University of GrazNovo Nordisk A/S; CSL BehringCompleted
-
University Health Network, TorontoQueen's University; Canadian Blood ServicesNot yet recruitingBleeding | Cardiac Surgery | Cardiopulmonary Bypass | PlateletsCanada